Alchornea

Alchornea: A Comprehensive Reference Article

1. Identity and Botanical Classification

Genus Overview

The genus Alchornea Sw. belongs to the Euphorbiaceae family. It was first described as a genus in 1788, by the Swedish botanist Olof Swartz. It is widespread in tropical and subtropical regions of Africa, South Asia, Australia, Latin America, and various oceanic islands. The genus is placed within the subfamily Acalyphoideae, tribe Alchorneae, subtribe Alchorneinae.

The genus Alchornea comprises 55 accepted species and two unresolved species which inhabit various ecosystems across all continents, with a special pantropical distribution. Across the genus as a whole, phytochemical studies have identified 396 bioactive compounds, primarily triterpenoids, alkaloids, flavonoids, and phenolics.

Medically Significant Species

While the genus contains dozens of species, three are the most extensively documented in the scientific and ethnopharmacological literature:

• Alchornea cordifolia (Schumach. & Thonn.) Müll.Arg. — the most widely studied species, native to tropical Africa, known in English as "Christmas bush."
• Alchornea floribunda Müll.Arg. — a West and Central African species also used medicinally.
• Alchornea laxiflora (Benth.) Pax & K. Hoffm. — used in Nigeria and other parts of West Africa.

The remainder of this article focuses primarily on A. cordifolia, as it is the subject of the vast majority of published scientific research on the genus, with supplementary information on other species where substantiated.

Botanical Description of Alchornea cordifolia

Alchornea cordifolia (Schum. & Thonn.) Müll. Arg. is an evergreen dioecious shrub which grows up to 8 m tall, distributed from the eastern part of Senegal to Kenya and Tanzania and throughout Central Africa to Angola. It is widespread in secondary forest and riverine forest, especially in marshy areas but sometimes in drier sites, from sea level up to 1,500 metres altitude. Its common name in English is the Christmas bush. It is known in the Asante-Twi dialect in Ghana as agyama.

Common Preparations and Forms

The leaves are the main part used, but the stem bark, stem pith, leafy stems, root bark, roots, and fruits are also employed. The leaves, root bark, and fruits are sold for medicinal purposes in local markets. Preparations documented in traditional and experimental contexts include:

• Aqueous decoctions and infusions: Extracts obtained by boiling A. cordifolia leaves in water are used as a remedy for stomach ulcers, venereal disease, cough, bronchial troubles, malaria, fever, rheumatic pain, sores, and toothache.
• Cold infusions: A cold infusion of the dried and crushed leaves acts as a diuretic.
• Mouthwash and topical applications: Leaf and root decoctions are widely used as mouthwash to treat ulcers of the mouth, toothache, and caries, and twigs are chewed for the same purposes.
• Topical poultice: The poultice of the leaves is used for the treatment of wounds.
• Leaf tea substitute: Dried leaves are substituted for tea.
• Standardized extracts: In experimental pharmacology, methanolic, ethanolic, ethyl acetate, aqueous, and chloroformic extracts of different plant parts have all been investigated.

---

2. Traditional and Historical Use

Geographical Scope and Cultures

Alchornea cordifolia is one of the most widely-used plants in traditional medicine throughout Africa, principally for inflammatory, antimicrobial, and parasitic diseases. From Senegal to Uganda, the leaves of Alchornea cordifolia (Schum. and Thonn.) Müll. Arg. (Euphorbiaceae) are successfully used by healers practicing traditional African medicine.

The plant is cultivated for its medicinal purposes in the Democratic Republic of Congo. In Cameroon, it is used in the treatment of urogenital infections.

Traditional Indications

Conditions for which the plant has enjoyed wide use are: coughs, gonorrhoea, infertility, prostatitis, bacterial infections, diarrhoea, ulcers, pain, inflammation, fever, and bronchial troubles. Specific traditional applications recorded in the literature include:

• Inflammatory and musculoskeletal conditions: The plant is used externally as an anti-inflammatory in numerous ailments such as toothache, piles, arthritis, and rheumatism.
• Gastrointestinal disorders: The plant is used internally in the treatment of gastrointestinal disorders, malaria, and respiratory and urinary tract infections.
• Dermatological uses: Studies on A. cordifolia were stimulated by its wide range of medicinal folk uses throughout Africa to treat diseases such as dermatitis, asthma, hepatitis, splenomegaly, vaginitis, metritis, and colitis.
• Wound care and leprosy: The leaves and root bark of A. cordifolia are externally applied to treat leprosy and as an antidote to snake venom.
• Other uses: Parts of this plant such as leaves, stem, and roots are used as painkillers and sedatives, for the treatment of stomach aches, nasopharyngeal infections, diarrhea, dysentery, hemorrhoids, and parasitic and bacterial infections.
• Reproductive health: Alchornea cordifolia leaf is traditionally used for the treatment of venereal diseases and for the enhancement of fertility throughout its area of distribution in Africa.
• Abortifacient: In Gabon, the plant has been recorded as an abortifacient.

Numerous reports of ethnopharmacological uses of species belonging to the genus exist mainly in Africa and Brazil, to treat different inflammatory and infectious diseases including arthritis, dysentery, infectious diseases, inflammation, intestinal disorders, fractures, leprosy, malaria, management of ringworm affections, muscle pain, rheumatism, and ulcer.

Other Alchornea Species in Traditional Use

Alchornea laxiflora (Benth.) Pax. & Hoffm. (Euphorbiaceae) root decoctions are traditionally used in the treatment of malaria and pain in Nigeria.

---

3. Key Phytochemical Constituents and Active Compounds

Overview of Chemical Classes

Phytochemical information indicates the identification of 95 compounds from A. cordifolia alone, including fatty acids, terpenoids, flavonoids, phenolic acids, and alkaloids. The major chemical classes are summarized below.

Alkaloids

The leaves, roots, and stem bark contain terpenoids, steroid glycosides, flavonoids, tannins, saponins, carbohydrates, and the imidazopyrimidine alkaloids alchorneine, alchornidine, and several guanidine alkaloids. The guanidine alkaloids — notably N¹,N²-diisopentenyl guanidine and N¹,N²,N³-triisopentenyl guanidine — have been isolated from leaves and root bark and demonstrated to have direct pharmacological relevance (see anti-inflammatory section below).

Phenolic Acids and Tannins

The use of A. cordifolia in traditional medicine has prompted many researchers to carry out various investigations in conjunction with its chemical composition; research teams have identified tannins, phenolic acids such as gallic acid, ellagic acid, and protocatechuic acid, as well as flavonoids including quercetin, hyperin, and guaijaverin, and some imidazopyrimidine alkaloids named alchorneine and alchornidine. The leaves also contain a range of hydroxybenzoic acids: gallic acid and its ethyl ester, gentisic acid, anthranilic acid, protocatechuic acid, and ellagic acid (alizarine yellow).

Flavonoids

Three flavonoids were isolated from the ethyl acetate fraction of the Alchornea cordifolia leaves: quercetin, myricetin 3-glucoside, and myricetin 3-rhamnoside. Additional flavonoids identified include hyperin (quercetin-3-galactoside), guaijaverin, and — of particular significance to sickle-cell disease research — quercitrin (quercetin-3-rhamnoside).

Terpenoids and Sterols

Phytochemical fractionation studies have identified several terpenoids and sterols. Daucosterol, acetyl aleuritolic acid, N¹,N²-diisopentenyl guanidine, and N¹,N²,N³-triisopentenyl guanidine were shown in a mouse ear oedema model to be more active than indomethacin, while β-sitosterol and di(2-ethylhexyl) phthalate were less effective.

Fatty Acids and Other Lipids

A C20 homolog of vernolic acid named alchornoic acid can be found in the seed oil. Several studies have reported the presence of nonacosane, oleic acid, octadecanal, and octen-3-ol as fatty acids.

Polysaccharides

Water-soluble polysaccharides have been extracted and fractionated from the leaves of A. cordifolia. The type II arabinogalactan fraction (designated AP-AU1) has been characterized as a particularly important immunomodulatory component (see below).

Phytochemical Profile of Aqueous Extracts

Phytochemical screening of an aqueous extract revealed the presence of phenols, tannins, triterpenes, flavonoids, alkaloids, anthraquinones, anthocyanins, saponins, and coumarins in the extract.

---

4. Established Mechanisms of Action

Anti-inflammatory Mechanisms

The ability of Alchornea cordifolia (Schum. and Thonn.) Müll. Arg. (Euphorbiaceae) leaves to inhibit human neutrophil elastase (HNE) and superoxide anion (O₂•–) activities was evaluated on aqueous extracts. From the IC₅₀ values obtained, it was concluded that A. cordifolia reduces HNE and O₂•– liberation. As the ethyl acetate extract offers a higher rate of total phenols than the aqueous extract as well as better scavenging activity, it is proposed that polyphenols are implicated in the activity of the plant; phenolic substances such as quercetin, myricetin-3-glucopyranoside, myricetin-3-rhamnopyranoside, and proanthocyanidin A2 were identified in the ethyl acetate extract.

In the mouse ear oedema model (topical, croton oil), six compounds were isolated from leaf and root bark extracts that exhibited significant topical anti-inflammatory activity; daucosterol, acetyl aleuritolic acid, N¹,N²-diisopentenyl guanidine, and N¹,N²,N³-triisopentenyl guanidine were shown to be more active than indomethacin.

Immunomodulatory Mechanisms

Fractions containing type II arabinogalactan had potent immunomodulatory activity; particularly, the high-molecular weight sub-fraction AP-AU1 (average M_r estimated to be 39.5 kDa) induced production of NO and cytokines [interleukin (IL)-1β, -6, -10, tumor necrosis factor (TNF)-α, and granulocyte-macrophage-colony stimulating factor (GM-CSF)] in human peripheral blood mononuclear cells and human and murine monocyte/macrophage cell lines in vitro. Furthermore, treatment with AP-AU1 induced phosphorylation of Akt2, p38δ/p38γ, p70S6K1, RSK2, and mTOR, as well as stimulation of NF-κB transcriptional activity. These results provide a molecular basis to explain a portion of the beneficial therapeutic properties of water extracts from Alchornea cordifolia leaves in traditional folk medicine of Africa.

Anti-sickling Mechanisms

Purified quercitrin inhibited the polymerisation of isolated HbS and stabilized sickle erythrocyte membranes. Metabolomic comparisons of blood samples indicated that quercitrin could convert HbSS erythrocyte metabolomes to be like HbAA; sickling was associated with changes in antioxidants, anaerobic bioenergy, and arachidonic acid metabolism, all of which were reversed by quercitrin.

---

5. Scientific Evidence by Area of Use

Important caveat: The scientific evidence base for Alchornea consists almost entirely of in vitro (cell-based) studies and in vivo animal experiments. To translate the pharmacological potential of the genus into clinical practice, a strategic focus on modern plant valorization is required; future research should focus on developing standardized oral formulations and topical preparations, and further research is needed to assess the efficacy and safety of the largely unexplored genus. No large-scale, randomized controlled clinical trials in humans have been published to date for any indication.

5.1 Anti-inflammatory Activity

Evidence level: Preclinical (animal and in vitro only)

The anti-inflammatory effects of the crude methanolic extract of Alchornea cordifolia leaves and five fractions were evaluated using egg-albumin-induced rat hind paw oedema as a model of inflammation. Fraction A2, which exhibited the most promising anti-inflammatory effect, was also subjected to analgesic and ulcerogenic tests; phytochemical analysis of the extracts showed the presence of terpenes, sterols, flavonoids, tannins, carbohydrates, glycosides, saponins, and traces of alkaloids.

At concentrations of 500 mg/kg and 1000 mg/kg, aqueous extracts exhibited anti-inflammatory activity and inhibited some mediators (histamine, 5-hydroxytryptamine, kinins, and prostaglandins) which cause inflammation.

The local and systemic anti-inflammatory properties of various extracts from Alchornea cordifolia have been validated in multiple pharmacological studies. These studies provide proof of ethnomedical claims and partly explain the mechanisms of the anti-inflammatory action of A. cordifolia leaves. However, all published evidence remains preclinical; no human interventional studies have been completed.

5.2 Antimicrobial Activity

Evidence level: Preclinical in vitro and limited in vivo animal models

Various antimicrobial screenings of A. cordifolia have revealed its effectiveness against a wide range of pathogenic microbes including gastrointestinal, skin, respiratory, and urinary tract pathogens, thus supporting the traditional use of the plant for the treatment of such ailments.

A BMC Complementary Medicine and Therapies study investigated the antibacterial activity against Escherichia coli: the antibacterial activity of the aqueous extract from leaves of Alchornea cordifolia was carried out in vitro on Escherichia coli, as well as in vivo on an E. coli-infected rat model. The extract exhibited a bacteriostatic activity with MIC value of 1500 μg/ml. In vivo, the oral administration of the extract showed a dose-dependent decrease of the bacterial load, as the extract at 232, 112, and 58 mg/kg was able to eradicate the infection after 9, 11, and 13 days of treatment, respectively.

Extracts showed a broad spectrum of activity against bacterial isolates with varying zones of inhibition ranging from 32 mm to 17 mm; the lowest minimum inhibitory concentration (MIC) assay for A. cordifolia was obtained with ethanol and methanol extracts against all bacterial species.

Alchornea cordifolia extracts have a very broad spectrum of activity and have also been suggested to be useful for treatment of various microbial infections. However, all this evidence is in vitro or in animal models, and no clinical trials in humans have established efficacy or appropriate dosing for infectious diseases.

5.3 Antiplasmodial Activity (Malaria)

Evidence level: In vitro and animal models; no clinical evidence

Extracts of the leaves of Alchornea cordifolia were studied for their antiplasmodial activities; chloroformic and ether extracts were found to be inactive while the ethanolic extract exhibited mild in vitro activity against Plasmodium falciparum. Fractionation of this extract led to the isolation of ellagic acid as the active constituent with IC₅₀ in the range of 0.2–0.5 μM.

For Alchornea laxiflora, the root extract and fractions were investigated for antimalarial activity against Plasmodium berghei infection in mice and antiplasmodial activity against chloroquine-sensitive (Pf 3D7) and resistant (Pf INDO) strains of Plasmodium falciparum using the SYBR green assay method.

5.4 Wound Healing

Evidence level: Animal models; no controlled human trials

A 10% w/w aqueous leaf extract of A. cordifolia cream in an excision wound model exhibited potent wound healing capacity with better wound closure (p<0.05) at day 1 and day 9 (p<0.001) compared with untreated wounds; histological investigations showed enhanced wound tissue proliferation, fibrosis, and re-epithelialisation compared with untreated wound tissues.

5.5 Anti-sickling Activity (Sickle Cell Anaemia)

Evidence level: In vitro; preliminary

Alchornea cordifolia is described in recent literature as a small tree native to tropical Africa whose leaves possess anti-sickling properties, particularly demonstrated through the superior action of its aqueous extract on sickle blood samples. A 2022 study published in the Journal of Clinical Medicine (PMC9024604) isolated quercitrin from A. cordifolia as a key anti-sickling agent. Sickling was associated with changes in antioxidants, anaerobic bioenergy, and arachidonic acid metabolism, all of which were reversed by quercitrin; the findings could inform efforts directed at developing an anti-sickling drug or quality control assessments of A. cordifolia preparations. This research used blood from a single patient, constituting highly preliminary evidence.

5.6 Immunomodulatory Activity

Evidence level: In vitro cell-line studies; no clinical trials

Polysaccharide fractions isolated from A. cordifolia demonstrated a potent immunomodulatory effect through the activation of human and murine monocyte/macrophages, resulting in modulation of nitric oxide and cytokine production, thereby enhancing resistance to infection. The arabinogalactan fraction AP-AU1 was characterized in detail, activating multiple intracellular signaling pathways including MAPK, Akt2, and NF-κB in cell-line experiments. This work remains in vitro and has not been replicated in human subjects.

5.7 Hepatoprotective Activity

Evidence level: Animal models only

Plant leaf extracts have been reported to have anti-inflammatory, hepatoprotective, antimicrobial, and antioxidant activities in animal studies. Research cited in the literature includes investigation of effects on diclofenac-induced liver and kidney injuries in rats: a comparative study investigated the effects of Alchornea cordifolia and Cassia spectabilis leaf extracts on diclofenac-induced hepatorenal injuries in rats and compared their activities. No human clinical data exist for this indication.

5.8 Antioxidant Activity

Evidence level: In vitro assays only

In ABTS and DPPH radical scavenging assays, the methanol extract (500.38 mg TE/g for DPPH and 900.64 mg TE/g for ABTS) exhibited the best ability, followed by the water and ethyl acetate extracts. The dichloromethane extract of A. cordifolia leaves shows significant phytochemical, antioxidant, and anti-inflammatory properties, with strong in vitro antioxidant and anti-inflammatory activity, outperforming aspirin in albumin denaturation and membrane stabilization, indicating promising therapeutic potential. These are in vitro results and their clinical relevance is not established.

5.9 Antidiarrhoeal Activity

Evidence level: Animal models

Several reports on the biological activities of A. cordifolia have shown the plant to possess antidiarrhoeal, hepatoprotective, antiviral, and antidiabetic properties in preclinical models. The antidiarrhoeal activity of the leaf extract was documented in Phytotherapy Research (Agbor et al., 2004, vol. 18, pp. 873–876), though this evidence derives from animal experimentation.

5.10 Anticancer / Cytotoxic Activity

Evidence level: In vitro cell-line studies only

The ethyl acetate extract of A. cordifolia was cytotoxic on HepG2 cells, and together with the infusion extracts showed potent cytotoxicity on B16 4A5 cells; mitochondrial membrane potential loss and increased ROS have been reported as a mode of apoptosis induction of plant extract. The methanolic and infusion extracts exerted comparatively higher cytotoxicity on human hepatocellular carcinoma cells (HepG2), with selectivity values above 1, thus showing much lower cell viability (<20%) in contrast to the ethyl acetate extract. No in vivo animal studies or human trials on anticancer activity have been published.

---

6. Body Systems and Health Areas of Association

Alchornea species are commonly used in traditional medicine to treat inflammation; infectious, gastrointestinal, respiratory, musculoskeletal, and dermatological disorders; as well as other diseases. Based on the published scientific literature, the body systems most consistently associated with Alchornea research include:

• Immune system: Immunomodulatory polysaccharides (arabinogalactans) activating macrophages and modulating cytokine production.
• Inflammatory pathways: Inhibition of neutrophil elastase, superoxide anion, and prostaglandin-mediated inflammation.
• Antimicrobial defense: Antibacterial, antifungal, and antiprotozoal activity against a wide spectrum of pathogens.
• Hematopoietic/sickle cell system: Anti-sickling properties via HbS polymerization inhibition (quercitrin).
• Hepatic system: Hepatoprotective effects documented in animal models.
• Gastrointestinal system: Antidiarrhoeal and spasmolytic activity.
• Integumentary system (skin and wounds): Wound-healing promotion documented in animal excision models.
• Respiratory system: Traditional use for coughs and bronchial conditions, though no mechanistic studies have fully elucidated this activity.

---

7. Dosage Forms and Dosages Reported in Studies

The following dosages reflect those reported in published preclinical or experimental studies only. No standardized human clinical dosing has been established for any indication.

• Topical anti-inflammatory (mouse ear oedema model): Six isolated compounds were applied in the mouse ear oedema model using croton oil at a dose of 90 μg/cm².
• Anti-hemorrhoidal aqueous extract (animal model): Concentrations of 500 mg/kg and 1000 mg/kg exhibited anti-inflammatory activity and inhibited inflammation mediators in an in vivo model.
• Antibacterial (in vivo rat model): Oral administration of the extract at 232, 112, and 58 mg/kg was able to eradicate E. coli infection after 9, 11, and 13 days of treatment respectively.
• Wound healing (cream formulation): A 10% w/w aqueous leaf extract cream was used in an excision wound model, exhibiting potent wound healing capacity.
• Antimicrobial (MIC values): The aqueous extract exhibited bacteriostatic activity with an MIC value of 1500 μg/ml against E. coli.
• Antiplasmodial (active constituent): Ellagic acid, identified as the active antiplasmodial constituent, had an IC₅₀ in the range of 0.2–0.5 μM in vitro.

---

8. Safety Considerations

Acute Toxicity

The acute toxicity study of the aqueous leaf extract showed LD₅₀ values of 8.6 g/kg in male mice and 3.8 g/kg in female mice. The results showed that the extract of A. cordifolia may be considered as slightly and almost non-toxic in female and male mice respectively.

Dose-dependent Hepatotoxicity Signals

Histology of liver and kidney at dose levels up to 1000 mg/kg in mice was normal and similar to vehicle-treated controls. However, liver sections of mice treated with 2000 mg/kg Alchornea extract showed perivascular aggregates of lymphocytes, eosinophilia, and pyknosis, evidence of hepatic damage. These results suggest that Alchornea cordifolia is relatively non-toxic but has the propensity to induce hepatic injury at high doses.

In the rat antibacterial study, an increase of inflammation at dose 232 mg/kg could suggest a toxicity effect of the extract at a relatively high dose. The infected rats showed a significant (p<0.05) increase in the level of serum creatinine, ALAT, and white blood cells; in treated rats, a significant increase in ALAT was observed at doses of 116 and 232 mg/kg, and a decrease in red blood cell count and serum protein levels was also observed.

Effects on Reproductive Parameters

Alchornea cordifolia leaf is traditionally used for the treatment of venereal diseases and for enhancement of fertility, but its oral administration in male rats was studied, including at doses up to 1600 mg/kg. The study in Andrologia (Ajibade & Olayemi, 2015) documented reproductive and toxic effects in male rats, suggesting that effects on reproductive parameters at high doses warrant caution, though direct human data are absent.

Potential Cytotoxicity Distinction

It was demonstrated that A. cordifolia extracts have no cytotoxic activity on polymorphonuclear cells (PMN) by measuring release of the cytosolic enzyme lactate dehydrogenase. However, the same plant extracts showed cytotoxic effects on cancer cell lines (HepG2 and B16 4A5) in separate cell-line experiments, reflecting extract- and concentration-dependent cytotoxicity.

Abortifacient Potential

Traditional use in Gabon records the plant as an abortifacient; in Gabon the plant is recorded as being used as an abortifacient. This traditional attribution has not been systematically evaluated pharmacologically, but it represents a documented concern for use during pregnancy.

Gaps in Safety Data

Further research on the pharmacological mechanism of action of this plant is recommended in order to unravel the pharmacokinetics, pharmacodynamics, clinical relevance, and toxicity of its extracts as well as constituents. There are still significant gaps in the completeness of understanding of A. cordifolia bioactivity, therapeutic value, and the roles played by each of the numerous phytoconstituents.

---

9. Summary of Evidence Strength

Across all investigated therapeutic areas, the evidence base for Alchornea — and especially A. cordifolia — is best characterized as preliminary to moderate at the preclinical level. Alchornea cordifolia is an important medicinal plant in African traditional medicine, and much pharmacological research has been carried out into its antibacterial, antifungal, and antiprotozoal properties, as well as its anti-inflammatory activities, with significant positive results in preclinical models. However, the link between activity and particular compounds is often not clear, although the flavonoids and tannins seem to play a major role, and more research is needed to elucidate these relations.

Future research should focus on the valorization of Alchornea species by developing standardized oral formulations and topical preparations that harness their validated anti-inflammatory and antimicrobial effects beyond traditional uses. No randomized controlled clinical trials have been conducted in humans for any indication, and the existing evidence base does not support definitive conclusions about therapeutic efficacy or safe dosing in humans.

References

• Aamer M. et al. (2026). The Genus Alchornea (Euphorbiaceae): A Comprehensive Review of Its Taxonomy, Traditional Uses, Phytochemistry, Pharmacological Potential, and Toxicology. Molecules, 31(10), 1726.
• Boniface P.K., Ferreira S.B., Kaiser C.R. (2016). Recent trends in phytochemistry, ethnobotany and pharmacological significance of Alchornea cordifolia (Schumach. & Thonn.) Muell. Arg. Journal of Ethnopharmacology.
• Pereira D.M. et al. (2021). Deeper Insights on Alchornea cordifolia Extracts: Chemical Profiles, Biological Abilities, Network Analysis and Molecular Docking. PMC / Frontiers in Pharmacology.
• Kouakou K. et al. (2013). Immunomodulatory activity of polysaccharides isolated from Alchornea cordifolia. Journal of Ethnopharmacology, 146(1):232–242.
• Kouakou K. et al. (2013). Immunomodulatory activity of polysaccharides isolated from Alchornea cordifolia. PMC Full Text.
• Mavar-Manga H. et al. (2008). Anti-inflammatory compounds from leaves and root bark of Alchornea cordifolia. Journal of Ethnopharmacology.
• Kouakou-Siransy G. et al. (2010). Effects of Alchornea cordifolia on elastase and superoxide anion produced by human neutrophils. Pharmaceutical Biology, 48:128–133.
• Osadebe P.O. & Okoye F.B. (2003). Anti-inflammatory effects of crude methanolic extract and fractions of Alchornea cordifolia leaves. Journal of Ethnopharmacology. PubMed.
• Banzouzi J.T. et al. (2002). In vitro antiplasmodial activity of extracts of Alchornea cordifolia and identification of an active constituent: ellagic acid. Journal of Ethnopharmacology. PubMed.
• Adeniyi O. et al. (2022). Isolation and Characterisation of Quercitrin as a Potent Anti-Sickle Cell Anaemia Agent from Alchornea cordifolia. Journal of Clinical Medicine, 11(8):2177.
• Kengni F. et al. (2017). Antibacterial activities and toxicological study of the aqueous extract from leaves of Alchornea cordifolia (Euphorbiaceae). BMC Complementary Medicine and Therapies.
• Antibacterial activities and toxicological study of the aqueous extract from leaves of Alchornea cordifolia (Euphorbiaceae). PubMed.
• Alchornea cordifolia — Overview. ScienceDirect Topics.
• Okeke I.N. et al. (2001). Antibacterial activity of Alchornea cordifolia stem bark. Fitoterapia.
• Systematic review on Alchornea laxiflora: Appraising therapeutical potentials of an underexplored medicinal herb. PMC.
• Antimalarial, antiplasmodial and analgesic activities of root extract of Alchornea laxiflora. PMC.
• Mavar-Manga H. et al. (2007). Alchornea cordifolia (Schumach. & Thonn.) Müll.Arg. PROTA / UCL Full Text.
• Ansah C. et al. (2009). Toxicity studies on Alchornea cordifolia leaf extract in mice. Journal of Science and Technology, 29:8–16. ResearchGate.
• Ajibade A. & Olayemi F. (2015). Reproductive and toxic effects of methanol extract of Alchornea cordifolia leaf in male rats. Andrologia.
• Alchornea cordifolia. Wikipedia (referencing cited primary botanical and chemical literature).
• Alchornea cordifolia — Useful Tropical Plants Database (referencing PROTA).
• Martínez C.A. et al. (2017). Medicinal plants from the genus Alchornea (Euphorbiaceae): A review of their ethnopharmacology uses and phytochemistry. Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas, 16(3):162–205.
• Use of Medicinal Plants in the Process of Wound Healing: A Literature Review. PMC. (citing Agyare et al., 2014 on A. cordifolia wound healing)
• Mini-review on ethnomedical uses, chemical constituents, pharmacological activities and toxicological study of Alchornea cordifolia. MedCrave Online.